SCHEMBL3961649

SCHEMBL3961649

COc1ccc(C2=CC(=O)CCC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 2/20 0.57
MAPK1 P28482 2/20 0.57
KMT2A Q03164 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
BACE1 P56817 2/20 0.50
PTGS1 P23219 2/20 0.47
PTGS2 P35354 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC6A3 Q01959 1/20 0.46
CYP1A2 P05177 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
MCL1 Q07820 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
BRD4 O60885 1/20 0.44
ME2 P23368 1/20 0.43
ME1 P48163 1/20 0.43
ME3 Q16798 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319811 0.88 ALDH1A1 (0.60) ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL22213562 0.83 EGFR (0.45) ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL20370344 0.83 ALDH1A1 (0.44) ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL678459 0.81 NCOA1 (0.62) ALDH1A1CYP1A2BRD4
SCHEMBL9326151 0.80 PDE4B (0.52) ALDH1A1MEN1MAPK1KMT2APTGS2
SCHEMBL5793895 0.80 PTGS2 (0.42) ALDH1A1MEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL5001532 0.79 NCOA1 (0.59) CYP1A2BRD4
SCHEMBL3519376 0.76 MAPK14 (0.41) ALDH1A1PTGS1PTGS2KDM4EMAPT
SCHEMBL28756264 0.76 MT-CO2 (0.53) ALDH1A1PTGS1PTGS2SLC6A3MAPT
SCHEMBL5225774 0.76 HTR2C (0.37) ALDH1A1MEN1MAPK1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509418-B2 Chromophoric compounds and UV-absorbing compositions LYGG CORPORATION (US) 2025-12-30 US disclosed
US-20250270164-A1 CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS LYGG CORPORATION 2025-08-28 US disclosed
US-11345652-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS (CA) 2022-05-31 US disclosed
US-20210017116-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2021-01-21 US disclosed
US-20200148623-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2020-05-14 US disclosed
US-10556853-B2 Anticonvulsant compounds OWEN-BARRY PHARMACEUTICALS INC. (CA) 2020-02-11 US disclosed
WO-2018129609-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2018-07-19 WO disclosed
US-20180194715-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2018-07-12 US disclosed
US-20180194715-A1 ANTICONVULSANT COMPOUNDS OWEN-BARRY PHARMACEUTICALS INC. (CA) 2018-07-12 US disclosed
US-20090298898-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2009-12-03 US disclosed
US-7569727-B2 N-{(4-{3-[2,6-dichloro-4-(3,3-dichloro-allyloxy)-phenoxy]-propoxy}-phenyl)-[(E)-ethoxyimino]-methyl}-2,2,2-trifluoroacetamide; exhibit valuable preventive and/or curative activity even at low rates of concentration, while being well tolerated by warm-blooded animals, fish and plants SYNGENTA CROP PROTECTION, INC. (US) 2009-08-04 US disclosed
EP-2080752-A1 Pesticidally active ketone and oxime derivatives Syngenta Participations AG (CH) 2009-07-22 EP disclosed
US-20080200525-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2008-08-21 US disclosed
US-20060128670-A1 Pesticidally active ketone and oxime derivatives SYNGENTA CROP PROTECTION, INC. 2006-06-15 US disclosed
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
EP-1638924-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES Syngenta Participations AG (CH) 2006-03-29 EP disclosed
WO-2004113273-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2004-12-29 WO disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed
WO-1998031697-A1 ARYL C-GLYCOSIDE COMPOUNDS AND SULFATED ESTERS THEREOF SANKYO COMPANY, LIMITED (JP) 1998-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270164-A1 CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS ERCC1, TYR, ERCC5 ALDH1A1 1196/4885MEN1 1001/4885MAPK1 3325/4885
US-20090298898-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES CHRM2, FOXO3, CHRM1 ALDH1A1 1934/4885MEN1 1164/4885MAPK1 1933/4885
US-12509418-B2 Chromophoric compounds and UV-absorbing compositions LBR, ERCC1, MC1R ALDH1A1 1591/4885MEN1 4477/4885MAPK1 4024/4885
US-20180194715-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885MEN1 4075/4885MAPK1 3911/4885
US-20210017116-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885MEN1 4075/4885MAPK1 3911/4885
US-20200148623-A1 ANTICONVULSANT COMPOUNDS GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885MEN1 4075/4885MAPK1 3911/4885
US-11345652-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885MEN1 4075/4885MAPK1 3911/4885
US-20060128670-A1 Pesticidally active ketone and oxime derivatives CHRM2, CHRM1, DDT ALDH1A1 1617/4885MEN1 738/4885MAPK1 2073/4885
US-20080200525-A1 PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES CHRM2, FOXO3, CHRM1 ALDH1A1 1934/4885MEN1 1164/4885MAPK1 1933/4885
US-10556853-B2 Anticonvulsant compounds GABRE, CACNA1B, GRIK5 ALDH1A1 1140/4885MEN1 4075/4885MAPK1 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.